Metabolic dysfunction associated steatotic liver disease is assessed with a liver panel, metabolic blood tests, a fibrosis score such as FIB-4, and—when indicated—ultrasound or elastography. Normal liver enzymes do not exclude MASLD; the central clinical task is identifying the smaller group with significant fibrosis before cirrhosis develops.
- MASLD diagnosis requires evidence of liver fat plus at least one cardiometabolic risk factor after other important causes are considered.
- ALT can be normal in MASLD; AASLD uses 19–25 U/L for women and 29–33 U/L for men as a clinically meaningful reference range.
- FIB-4 jos 1.3 usually indicates low risk of advanced fibrosis in adults aged 35–65 when the test is done outside acute illness.
- FIB-4 sur 2.67 warrants secondary fibrosis assessment or hepatology referral rather than watchful waiting alone.
- Age over 65 changes FIB-4 interpretation: a threshold of 2.0, rather than 1.3, reduces false-positive results.
- Transient elastography below 8 kPa generally makes advanced fibrosis unlikely, while values above 12 kPa need specialist interpretation.
- MRI-PDFF of 5% or more is commonly used to define measurable hepatic fat in research and specialist practice.
- Platelet decline can be an early indirect clue to portal hypertension, even when albumin and bilirubin remain normal.
- Alcohol history matters because 20–50 g/day for women or 30–60 g/day for men may meet MetALD rather than pure MASLD criteria.
- Repetir lo temps is usually 1–2 years for people with type 2 diabetes or multiple metabolic risks and 2–3 years for lower-risk patients.
What MASLD testing can—and cannot—tell you
MASLD tests answer two separate questions: is fat likely present in the liver, and is there evidence of fibrosis that changes long-term risk? A routine liver panel can raise suspicion, but imaging confirms steatosis and non-invasive fibrosis tests sort who needs closer assessment.
Metabolic dysfunction associated steatotic liver disease replaces the older term NAFLD in current clinical language. It describes hepatic steatosis plus one or more cardiometabolic risk factors—such as increased waist circumference, prediabetes, type 2 diabetes, hypertension, low HDL cholesterol, or raised triglycerides—and requires a thoughtful search for competing causes of fat in the liver.
The uncomfortable truth is that no single MASLD blood test diagnoses the condition. As Dr. Thomas Klein, I explain that ALT is a leakage signal, not a fat meter: it may rise with liver-cell stress, yet a person can have substantial liver fat or even fibrosis with a normal ALT. Our guia del panell hepàtic explains what is and is not included in a typical panel.
Kantesti es un Analizador de tèst de sang d'IA that places AST, ALT, platelets, glucose, HbA1c, triglycerides, and alcohol-related context into one timeline rather than treating a flagged enzyme as a diagnosis. That matters because a raised ALT after a hard workout, a new medicine, or a viral illness is interpreted very differently from a persistent metabolic pattern across 6–12 months.
The clinical aim is fibrosis triage
Most people with MASLD will not develop cirrhosis. The key prognostic variable is fibrosis stage, especially stage F3–F4, which is why modern pathways begin with inexpensive blood-based triage before specialist imaging.
Who should consider fatty liver screening
People with type 2 diabetes, obesity with metabolic complications, or two or more cardiometabolic risk factors are the highest-priority groups for fibrosis screening. Screening is aimed at advanced fibrosis risk, not at finding harmless fat alone.
Type 2 diabetes is the clearest practical trigger for MASLD tests because diabetes increases the likelihood of steatohepatitis and fibrosis even at a body weight that appears unremarkable. The 2024 EASL-EASD-EASO guideline recommends case-finding for MASLD with fibrosis in people with type 2 diabetes, abdominal obesity plus metabolic risk, or persistently raised liver enzymes (EASL-EASD-EASO, 2024).
I also screen the lean patient with high triglycerides, hypertension, sleep apnoea, polycystic ovary syndrome, or a first-degree relative with cirrhosis. A waist measurement can be more revealing than BMI here; central adiposity is metabolically active, and cutoffs del sindròme metabolic help put fasting glucose, blood pressure, HDL, and triglycerides together.
Routine population ultrasound for everyone is not supported by the same evidence as targeted risk assessment. If you have no metabolic risk factors, normal liver tests, and no relevant family or medication history, indiscriminate fatty liver screening can produce incidental findings without improving outcomes.
Pregnancy and children need separate pathways
Pregnancy alters liver tests and is not a suitable time to apply adult fibrosis scores without clinician input. In children, paediatric reference ranges and specialist pathways are needed; adult FIB-4 cutoffs should not be used.
Routine MASLD blood tests: the useful first panel
The first MASLD blood tests are ALT, AST, alkaline phosphatase, GGT, bilirubin, albumin, platelet count, fasting glucose or HbA1c, and a lipid panel. These results identify alternative liver patterns, metabolic drivers, and the inputs needed for FIB-4.
ALT and AST are measured in U/L, but their laboratory upper limits vary substantially by country and assay. AASLD notes that ALT values of 19–25 U/L per las femnas e 29–33 U/L pels òmes are more clinically appropriate than many laboratory reference limits for chronic liver injury; an ALT of 38 U/L may therefore deserve attention despite appearing only mildly raised (Rinella et al., 2023).
GGT is not a MASLD diagnostic test, yet it is often helpful when ALT is mildly elevated and alcohol, medication, or biliary disease is part of the differential. A disproportionate alkaline phosphatase or GGT rise, especially with direct bilirubin elevation, shifts the investigation toward cholestasis rather than uncomplicated steatosis; see our guide to ALP, GGT and bilirubin patterns.
Albumin, bilirubin, and INR are measures of liver synthetic function, not early fat accumulation. Albumin below about 35 g/L, rising bilirubin, or an elevated INR in someone with suspected chronic liver disease deserves prompt medical review because these abnormalities may indicate advanced disease or another process entirely.
Metabolic tests that explain why liver fat develops
HbA1c, fasting glucose, triglycerides, HDL cholesterol, and blood pressure define the metabolic environment that drives MASLD. These measures often predict progression more usefully than the ALT level alone.
HbA1c of 5.7–6.4% indica una prediabèta, mentre que 6.5% o mai naut on an appropriate confirmatory pathway supports diabetes. In clinic, I am particularly alert to a patient with HbA1c 6.1%, triglycerides 220 mg/dL, and an ALT near the laboratory limit: that combination can signal insulin resistance long before overt diabetes appears.
Triglicerids de 150 mg/dL o mai naut are one metabolic syndrome criterion, and levels above 500 mg/dL shift the immediate concern toward pancreatitis prevention. A non-fasting sample is often adequate for cardiovascular assessment, but fasting triglycerides can clarify a confusing result; our article on triglicèrids aprèp aver manjat cubre las distinciones prácticas.
Fasting insulin and HOMA-IR can be informative in selected patients, but neither is required to diagnose MASLD or calculate fibrosis risk. I caution against chasing insulin numbers alone: insulin assays differ between laboratories, whereas HbA1c, glucose, waist size, and triglyceride trends usually guide decisions more reliably.
Normal HbA1c does not erase metabolic risk
A person can have normal HbA1c and still have MASLD, particularly with visceral adiposity, genetic susceptibility, or high triglycerides. HbA1c also becomes less reliable after transfusion, with some haemoglobin variants, and in conditions that change red-cell lifespan.
Tests clinicians use to rule out other liver causes
MASLD is not diagnosed by excluding nothing; clinicians must consider viral hepatitis, alcohol exposure, medicines, iron overload, autoimmune disease, and less common inherited disorders. The exact tests depend on age, enzyme pattern, history, and imaging.
Hepatitis B surface antigen and hepatitis C antibody are common early checks when aminotransferases remain elevated. A person may have both MASLD and viral hepatitis, so finding metabolic risk factors should never stop a standard liver work-up; our overview of hepatitis C testing clues explains why symptoms are often absent.
Ferritin is frequently raised in MASLD because it behaves as an acute-phase reactant, not necessarily because iron stores are excessive. Ferritin above 300 ng/mL en las femnas o 400 ng/mL en los òmes can prompt iron studies, but transferrin saturation persistently above 45% is the more useful clue that hereditary haemochromatosis may need evaluation; see iron overload lab clues.
Autoimmune markers, immunoglobulins, ceruloplasmin, alpha-1 antitrypsin testing, and medication review are selective—not blanket—tests. In a 28-year-old with ALT 180 U/L and no metabolic risk, I would not be reassured by a slightly fatty ultrasound; age and the enzyme pattern make alternative causes much more important.
Alcohol quantity changes the diagnostic label
As of September 15, 2026, EASL describes MetALD when MASLD coexists with alcohol intake of 20–50 g/day in women or 30–60 g/day in men. Amount, frequency, binge pattern, prior use, and under-reporting all affect interpretation, so a single yes-or-no alcohol question is inadequate.
FIB-4: the first fibrosis score to know
FIB-4 uses age, AST, ALT, and platelet count to estimate the likelihood of advanced fibrosis. A result below 1.3 is usually reassuring in adults aged 35–65, while a result above 2.67 needs secondary assessment or referral.
The formula is age × AST divided by platelet count × the square root of ALT; calculator outputs are safer than manual arithmetic because platelets may be reported as 10⁹/L or 10³/µL. FIB-4 is designed to rule out advanced fibrosis efficiently, not to prove cirrhosis, and our FIB-4 calculation guide walks through the units.
For people over 65 ans, using the usual 1.3 threshold creates many false alarms because age is part of the formula. A cutoff of 2.0 is preferred for low-risk exclusion in this group; conversely, FIB-4 performs poorly below age 35 and should not be treated as a clean bill of liver health in younger adults.
Do not calculate FIB-4 during pneumonia, a severe flare of illness, acute hepatitis, or immediately after an event likely to raise AST or lower platelets. A 52-year-old marathon runner with AST 89 U/L after a race can generate a misleading score—muscle stress and temporary enzyme shifts are not liver fibrosis.
Second-line MASLD blood tests after FIB-4
ELF, FibroTest-type panels, and other proprietary scores refine fibrosis risk when FIB-4 is indeterminate or high. ELF at 9.8 or above supports concern for advanced fibrosis, but it still does not replace clinical assessment.
The Enhanced Liver Fibrosis test combines hyaluronic acid, PIIINP, and TIMP-1—markers related to matrix turnover rather than liver enzymes. In AASLD pathways, an ELF score of 9.8 or higher can identify people at increased risk of advanced fibrosis, and 11.3 or higher is associated with a higher risk of liver-related events in advanced disease.
Kantesti es un servici d’interpretacion de tests de l’IA that can identify when the exact ingredients needed for FIB-4 are present and flag when a result sits in the indeterminate zone. It cannot order imaging, establish fibrosis stage, or substitute for a clinician examining the complete record; those boundaries are deliberate.
Scores such as APRI, NAFLD Fibrosis Score, and FAST may appear in specialist letters, but they are not interchangeable. APRI can be distorted by non-liver AST elevations, while the NAFLD Fibrosis Score includes BMI and albumin; a falling platelet trend is often more actionable than any one borderline algorithm result, as discussed in our cirrhosis lab clues.
Why fibrosis biomarkers occasionally disagree
Inflammatory illness, reduced kidney function, congestive heart failure, and age can influence some fibrosis markers. When a low FIB-4 and high ELF conflict, elastography and specialist review are usually more useful than repeating both tests immediately.
Ultrasound and elastography: what imaging adds
Ultrasound can identify moderate-to-severe steatosis, while vibration-controlled transient elastography estimates liver stiffness and often gives a fat-related CAP measurement. Elastography below 8 kPa generally makes advanced fibrosis unlikely in MASLD.
Standard ultrasound is accessible and useful, but it misses mild fat accumulation and cannot reliably stage fibrosis. A report stating “echogenic liver” supports steatosis in the right clinical context; it does not tell you whether liver cells are inflamed or whether fibrosis is progressing.
Transient elastography sends a painless vibration through the liver to estimate stiffness in kilopascals. In common MASLD pathways, less than 8 kPa suggests low risk of advanced fibrosis, 8–12 kPa is a grey zone, and above 12 kPa increases concern—yet meals, acute inflammation, congestion, cholestasis, and measurement quality can all raise stiffness.
I ask patients to fast for at least 3 oras before elastography when their centre requests it, because a recent meal can transiently increase stiffness. Higher BMI may require an XL probe, and a technically limited scan should be repeated rather than treated as bad news; our high AST follow-up guide helps explain why AST needs context.
CAP is a fat estimate, not a fibrosis stage
Controlled attenuation parameter, or CAP, estimates ultrasound signal loss caused by liver fat. Its values are device-specific and less useful for monitoring small changes than for supporting the overall diagnosis of steatosis.
MRI-PDFF and MRE: when specialist imaging helps
MRI-PDFF quantifies liver fat, and magnetic resonance elastography measures stiffness with greater accuracy than ultrasound-based elastography in many complex cases. MRI-PDFF of 5% or more is commonly used as evidence of hepatic steatosis.
MRI-PDFF measures the proportion of mobile protons attributable to fat and is excellent for research, trials, and ambiguous cases. A fall of roughly 30% relative MRI-PDFF has been associated with histologic improvement in treatment studies, but this is not a personal treatment target to pursue without specialist guidance.
MRE samples a much larger portion of liver than a small tissue core and can be especially helpful when transient elastography is unreliable. In specialist algorithms, MRE stiffness around 3.6 kPa or higher raises concern for advanced fibrosis, though scanner method and clinical setting affect the threshold.
Neither MRI test is routinely necessary for a low FIB-4, normal synthetic function, and reassuring elastography. The expensive scan is most valuable when it resolves a genuine decision: for example, conflicting blood scores in a person being considered for hepatology follow-up, not simply because an ultrasound found fat.
Imaging does not replace cardiometabolic care
A precise liver-fat percentage does not measure cardiovascular risk, which remains a leading cause of illness in MASLD. Lipids, blood pressure, diabetes treatment, sleep apnoea, and smoking status still need active management.
When a liver biopsy is still considered
Liver biopsy is now reserved for selected cases where non-invasive tests conflict, another diagnosis is plausible, or confirming steatohepatitis and fibrosis would change management. It is not the routine first test for MASLD.
A tissue examination can distinguish simple steatosis from steatohepatitis and stage fibrosis directly, but a tiny core may not represent the whole liver. Sampling variation is one reason I do not present biopsy as an automatic “gold standard” answer when high-quality elastography and blood tests agree.
Biopsy discussions are more common with unexplained ALT elevations above 6 meses, suspected autoimmune hepatitis, high ferritin with possible iron overload, or discordant tests such as FIB-4 0.8 with stiffness 15 kPa. The decision should include bleeding risk, medication review, and whether the result will change treatment or surveillance.
Dr. Thomas Klein’s practical rule is simple: test escalation should answer a question that changes the plan. Kantesti AI organizes longitudinal results for that conversation, while our manièra de validacion medica describes why algorithmic interpretation is designed as decision support, not diagnosis.
A biopsy result can still be incomplete
Fibrosis can be unevenly distributed, and steatohepatitis activity can fluctuate with recent weight change, alcohol use, and medications. A low-stage biopsy from years ago should not override new signs of portal hypertension or worsening non-invasive tests.
Common MASLD result patterns and what they mean
The most common MASLD pattern is mildly raised ALT with metabolic risk and preserved bilirubin, albumin, and platelet count; this suggests liver stress but not necessarily fibrosis. A low platelet count or rising stiffness changes the concern considerably.
Pattern one is ALT 45 U/L, AST 32 U/L, platelets 260 ×10⁹/L, HbA1c 6.2%, and triglycerides 210 mg/dL. This is a reasonable setting for FIB-4 and metabolic intervention, but it is not proof of advanced disease; repeating the panel after addressing alcohol and medication confounders is often sensible.
Pattern two is AST 58 U/L, ALT 45 U/L, platelets 135 ×10⁹/L, and FIB-4 above 2.67. The combination of AST predominance and declining platelets deserves urgent fibrosis assessment because platelets may fall as portal pressure rises—although alcohol, immune conditions, and laboratory artefact also need consideration.
Kantesti AI interprets MASLD-related biomarkers by comparing present results with prior values, age-adjusted FIB-4 thresholds, and coexisting metabolic markers rather than assigning meaning to an isolated high flag. A sudden platelet change should also prompt a check for l’agregacion de plaquetas amb EDTA, which can create a falsely low count.
AST:ALT ratio is a clue, not a verdict
An AST:ALT ratio above 1 can occur with advanced fibrosis, alcohol exposure, muscle injury, or cirrhosis, but it is not diagnostic by itself. Creatine kinase can help when strenuous exercise or muscle symptoms make AST origin uncertain.
How often to repeat MASLD tests
Repeat MASLD testing every 1–2 years is reasonable for people with type 2 diabetes or at least two metabolic risk factors when FIB-4 is low; lower-risk patients are often reassessed every 2–3 years. Repeat sooner when liver tests change, symptoms develop, or a new medicine is introduced.
Liver enzymes can move by 10–20% between visits because of exercise, alcohol, intercurrent illness, weight change, and ordinary biological variation. A repeat result is more useful when it is collected under comparable conditions: avoid unusually hard exercise for 48–72 hours, disclose supplements, and use the same laboratory where practical.
Weight loss can briefly raise ALT during rapid fat mobilisation, particularly in the first few weeks of a restrictive programme. That short-lived rise should be interpreted alongside symptoms, bilirubin, alkaline phosphatase, and the magnitude of change; our guide to ALT aprèp una pèrda de pes explica aqueste patròn contreintuïtiu.
Kantesti es un plataforma d’interpretacion de biomarcaires per IA that lets people compare serial liver, glucose, lipid, and platelet results without losing the original laboratory ranges. Trend graphs are useful prompts for a clinician conversation, but a stable-looking graph does not replace fibrosis reassessment at the recommended interval.
Do not repeat a fibrosis score during acute illness
FIB-4 should be deferred until acute illness has resolved because AST and platelet count may be temporarily distorted. In my experience, repeating a score 4–12 weeks after recovery is often more informative than acting on an inpatient calculation.
How to prepare for MASLD blood tests and scans
Most liver tests do not require fasting, but fasting for 8–12 hours can clarify triglycerides and some metabolic measurements. Elastography centres commonly ask for at least 3 hours without food to reduce meal-related stiffness variation.
Bring an accurate list of prescriptions, over-the-counter pain medicines, bodybuilding products, herbal preparations, and recent antibiotics. Supplements marketed for “detox” are not automatically benign; concentrated green tea extract, anabolic products, and multi-ingredient preparations can cause liver injury, as reviewed in our liver supplement safety article.
Avoid binge alcohol and unusually intense exercise for 48–72 oras before a planned liver panel if the aim is to establish a baseline, unless your clinician has told you otherwise. Do not stop prescribed medicines simply to improve a result; write down timing and dose so the interpreting clinician can account for them.
For ultrasound or elastography, ask whether your local service requests fasting and whether you need an XL probe because of body size. A failed or technically unreliable scan is a quality issue, not a personal failure, and repeating it at an experienced centre is entirely reasonable.
Save context with each result
Record recent illness, alcohol intake, exercise, new medications, and weight change beside the laboratory date. This simple habit can prevent a harmless transient ALT rise from becoming months of unnecessary anxiety.
Red flags that need prompt liver review
Jaundice, dark urine, pale stools, confusion, vomiting blood, black stools, abdominal swelling, or rapidly worsening fatigue need urgent medical assessment rather than routine MASLD follow-up. These features may indicate cholestasis, liver failure, gastrointestinal bleeding, or another serious condition.
Urgent review is also appropriate for ALT or AST above 10 times the local upper limit, bilirubin above 3 mg/dL o aperaquí 50 µmol/L with symptoms, INR elevation not explained by anticoagulants, or new platelets below 100 ×10⁹/L. These cutoffs are triage signals, not a diagnosis, and local emergency advice should take precedence.
Referral to hepatology is usually appropriate for FIB-4 above 2.67, elastography above about 12 kPa, suspected cirrhosis, unexplained persistent aminotransferase elevation, or diagnostic uncertainty. The question is not whether a patient has “failed” lifestyle change; it is whether they need surveillance for portal hypertension, liver cancer, or complications.
El contingut mèdic de Kantesti es revisa amb aportacions de la nostra Conselh Consultatiu Medical, but an app cannot evaluate jaundice, abdominal tenderness, mental status, or fluid retention. If symptoms are new or escalating, seek in-person care first and interpret uploaded results afterward.
Symptoms are often absent until late disease
Early fibrosis commonly causes no specific symptom, which is why risk-based testing matters. Conversely, fatigue alone is common and should not be assumed to be from MASLD without evaluating sleep, thyroid disease, anaemia, mood, and medication effects.
A patient-first plan after MASLD results
After MASLD testing, the next step is usually risk stratification rather than panic: confirm metabolic drivers, calculate FIB-4, arrange elastography only when indicated, and set a repeat schedule. The goal is to prevent advanced fibrosis while treating cardiovascular risk at the same time.
Ask your clinician four concrete questions: Do I have confirmed steatosis? What is my FIB-4 with the correct age cutoff? Do I need elastography or ELF? When should we repeat testing? These questions turn a vague “fatty liver” label into a plan with measurable checkpoints.
For many patients, a sustained 5% weight reduction improves liver fat, while 7–10% is more likely to improve steatohepatitis and fibrosis-related measures; the precise response varies with diabetes treatment, physical activity, sleep, genetics, and alcohol. Mediterranean-style eating, resistance training, aerobic activity, and evidence-based treatment of diabetes or obesity belong in the same plan, not in competing camps.
Kantesti AI is used by people across 127 countries to organise multilingual laboratory reports and track changes between appointments. If you want to understand how result extraction and pattern analysis work, our guia de tecnologia amb IA explains the safeguards; your treating clinician remains the person who confirms diagnosis and treatment.
What improvement looks like
Improvement may appear as lower triglycerides, better HbA1c, a falling ALT, stable platelets, and reassuring fibrosis assessment—not necessarily a perfect enzyme value at every draw. A result trend should be judged over months, not days.
Questions frequentas
Quins analisis de sang s'utilizan per la MASLD?
Los tests sanguins per la MASLD includon de'n general ALT, AST, fosfatasa alcalina, GGT, bilirubina, albumina, estimacion de plaquetas, HbA1c o glucosa en jeun, e un panel lipidic. Los clinicians utilizon l'edat, AST, ALT e lo'estimacion de plaquetas per calcular FIB-4, ont un resultat de mens de 1.3 indica generalament un bas risc de fibrosi avançada en adults de 35 a 65 ans. Aqueles tests non provan pas dirèctament la grassa del fetge, doncas que l'ecografia, l'elastografia, o l'IRM pòdon èsser encara necessaris. Las anormalitats persistentas devon tanben provocar de verificacions per l'epatita virala, la damatja ligada a l'alcòl, los medicaments, la sobrecàrga de fèrre, e d'autras malautias del fetge.
Se pòt aver MASLD amb d'enzims de fetge normals ?
Oui, la malautiá de fetge gras associada a la disfunción metabolica se pòt presentar amb de valors d'ALT e AST normals. L'ALT reflèta lo stress actual de las cellulas del fetge puslèu que la quantitat de grassa o de fibrosi del fetge, de sòrta que d'enzimas normals ne pòdon pas excluir de MASLD clinicament importantas. L'AASLD considèra que las valors d'ALT per dessús aperaquí 19–25 U/L per las femnas e 29–33 U/L per los òmes son potencialament significativas quitament quand un interval de laboratòri es mai larg. Las personas que an de diabèta de tipe 2 o de multiples riscs metabolics devon discutir de l'evaluacion de la fibrosi quitament se lor analisi del fetge es normal.
Quina es una pontuacion FIB-4 preocupanta?
Un resultat FIB-4 superior a 2,67 es preocupant per una fibrosi avançada e implica generalament una elastografia, un tèst ELF, o una referéncia en epatologia. Una valor en dejós de 1,3 es de còps que i a un bas risc per leis adults de 35-65 ans, mentre que 1,3-2,67 es una zòna indeterminada que necessita un segond tèst mai que de rassurància o d'alarma. Per leis adults de mai de 65 ans, un bas risc de 2,0 es frequentament utilizat car l'atge infla lo resultat. FIB-4 deuriá pas èsser interpretat pendent una malautiá aguda, e es mens fisadís cheus mainats de mens de 35 ans.
Es l'ecografia sufisenta per diagnosticar la malautiá del fetge gras?
L'ecografia pòt sostenir un diagnòstic d'esteatosi epaticad'intensitat moderada a severa, mas pòt mancar de grassa lleu e pòt pas classificar precisament la fibrosi. Un fetge ecogènic a l'ecografia destria pas la grassa simpla de l'esteatoepatitis o de la cirrosi. L'elastografia transeünciala apond una estimacion de la rigiditat: las valors en devath de 8 kPa fan generalament la fibrosi avançada impossibla, mentre que las valors en dessús de 12 kPa an besonh d'una interpretacion especializada. L'IRM-PDFF es mai precisa per mesurar la grassa epaticad, mas es pas regularament necessària per cada pacient.
Do I need to fast before MASLD blood tests?
Most liver-panel tests do not require fasting, but fasting for 8–12 hours can improve interpretation of triglycerides, fasting glucose, and fasting insulin when those are being measured. Avoid unusually strenuous exercise and binge alcohol for 48–72 hours before a baseline liver panel because both can temporarily affect AST, ALT, and triglycerides. Elastography services often request at least 3 hours without food because a recent meal can increase liver stiffness measurements. Never stop prescribed medication solely to prepare for testing unless a clinician specifically instructs you to do so.
How often should FIB-4 be repeated in MASLD?
People with type 2 diabetes or two or more metabolic risk factors and a low FIB-4 commonly repeat fibrosis risk assessment every 1–2 years. Lower-risk people with a reassuring FIB-4 can often be reassessed every 2–3 years, although a persistent ALT rise, falling platelet count, new diabetes, or major weight change may justify earlier testing. FIB-4 uses age, AST, ALT, and platelets, so it should be recalculated from a stable outpatient blood test rather than during an acute illness. A clinician may choose a shorter interval when elastography or other findings are borderline.
Obtén uèi una analisi de sang amb IA
Joinhètz mai de 2 milions d’utilizaires al mond que confian en Kantesti per una analisi instantanèa e precisa dels analisis de laboratòri. Mandatz vòstres resultats analisi de sang e recebetz una interpretacion complèta de 15,000+ biomarcadors en segondas.
📚 Publicacions de recerca citadas
Klein, T., Mitchell, S., & Weber, H. (2026). aPTT Gama Normal: D-dimèr, Proteïna C Guia de coagulacion sanguina. Kantesti IA Recèrca Medicala.
Klein, T., Mitchell, S., & Weber, H. (2026). Guida de proteïnas sèricas: Globulinas, albumina e tèst de sang de rapòrt A/G. Kantesti IA Recèrca Medicala.
📖 Referéncias mèdicas externes
⚕️ Avertiment medical
Aqueste article es solament per tòcas educatius e constituís pas de conselh medical. Consultatz totjorn un professional de la sant qualificat per las decisions de diagnostica e de tractament.
Senhals de confiança E-E-A-T
Experiéncia
Revisión clinica menada pel metge de las practicas d’interpretacion de las analisis.
Expertisa
Fòcus sus la medicina de laboratòri sus cossí los biomarcadors se comportan dins un contèxte clinic.
Autoritat
Escrich pel Dr. Thomas Klein amb revisión pel Dr. Sarah Mitchell e Prof. Dr. Hans Weber.
Fisança
Interpretacion basada sus d’evidéncias amb de camins de seguiment clars per reduzir l’alarmisme.